Global immuno-oncology assays market is estimated to be valued at USD 4.98 Bn in 2024 and is expected to exhibit a CAGR of 11.2% during the forecast period (2024-2031). Immuno-oncology assays help analyze the expression of biomolecules like proteins that are relevant for cancer immunotherapies. These assays aid in tumor profiling, treatment strategies, and development of immunotherapies. They help evaluate expression of immune biomarkers, which provides crucial insights into cancer-immune interactions and offers direction for targeted therapies. Advancements in fields like proteomics, genomic analysis, and multiplex technologies have enabled development of high-throughput immuno-oncology assays. Their ability to gauge pre-existing antitumor immune responses and predict treatment outcomes makes them integral tools in precision oncology.
Market Dynamics:
The global immuno-oncology assays market growth is driven by factors such as growing demand for targeted cancer therapies, rising adoption of combinational immunotherapies, increasing R&D investments by pharmaceutical companies, and improving availability of companion diagnostic tests. However, the market faces restraints in terms of high costs associated with immuno-oncology assays and limited reimbursement for such tests. Meanwhile, ongoing research on biomarkers and development of affordable immuno-oncology assays present significant opportunities for market players.
Key Features of the Study:
- This report provides an in-depth analysis of the global immuno-oncology assays market and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global immuno-oncology assays market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this includes Charles River Laboratories, F. Hoffmann-La Roche Ltd, llumina, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Invivoscribe, Inc., QIAGEN, PerkinElmer Inc., Sartorius AG, Bio-Rad Laboratories, Inc., Bruker Spatial Biology, Inc., Nexelis, Reaction Biology, Crown Bioscience, HTG Molecular Diagnostics, Inc., Axion BioSystems, Inc, and BioTherapeutics LLC
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global immuno-oncology assays market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology assays market
Detailed Segmentation-
- By Product:
-
- By Technology:
-
- Immunoassay
- PCR
- NGS
- Fow Cytometry
- Others
- By Indication:
-
- Colorectal Cancer
- Lung Cancer
- Melanoma
- Bladder Cancer
- Others
- By Application:
-
- Clinical Diagnostics
- Research and Development
- By Region:
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
-
- Charles River Laboratories
- Hoffmann-La Roche Ltd
- llumina, Inc.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Invivoscribe, Inc.
- QIAGEN
- PerkinElmer Inc.
- Sartorius AG
- Bio-Rad Laboratories, Inc.
- Bruker Spatial Biology, Inc.
- Nexelis
- Reaction Biology
- Crown Bioscience
- HTG Molecular Diagnostics, Inc.
- Axion BioSystems, Inc
- BioTherapeutics LLC
